Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/943409 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691419286962176 |
|---|---|
| author | Shivi Agrawal Malav Joshi John B. Christoforidis |
| author_facet | Shivi Agrawal Malav Joshi John B. Christoforidis |
| author_sort | Shivi Agrawal |
| collection | DOAJ |
| description | Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis. |
| format | Article |
| id | doaj-art-e79ad0100c29407f8842da7fc1121142 |
| institution | DOAJ |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e79ad0100c29407f8842da7fc11211422025-08-20T03:21:02ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/943409943409Vitreous Inflammation Associated with Intravitreal Anti-VEGF PharmacotherapyShivi Agrawal0Malav Joshi1John B. Christoforidis2Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USARetina Division, Department of Ophthalmology, University of Arizona Medical Center, 655 N. Alvernon Way, Suite 108, Tucson, AZ 85711, USAVascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.http://dx.doi.org/10.1155/2013/943409 |
| spellingShingle | Shivi Agrawal Malav Joshi John B. Christoforidis Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy Mediators of Inflammation |
| title | Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy |
| title_full | Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy |
| title_fullStr | Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy |
| title_full_unstemmed | Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy |
| title_short | Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy |
| title_sort | vitreous inflammation associated with intravitreal anti vegf pharmacotherapy |
| url | http://dx.doi.org/10.1155/2013/943409 |
| work_keys_str_mv | AT shiviagrawal vitreousinflammationassociatedwithintravitrealantivegfpharmacotherapy AT malavjoshi vitreousinflammationassociatedwithintravitrealantivegfpharmacotherapy AT johnbchristoforidis vitreousinflammationassociatedwithintravitrealantivegfpharmacotherapy |